– USA, MA – Atavistik Bio, a biotechnology company discovering the next generation of precision allosteric therapeutics, announced the appointment of Dr. Mohammad Hirmand (M.D.) to its Board of Directors.
About Dr. Mohammad Hirmand
Dr. Hirmand is currently co-founder, EVP, and CMO of Avenzo Therapeutics. Previously, Dr. Hirmand served as EVP and CMO for Turning Point Therapeutics, which Bristol Myers Squibb acquired. Prior to joining Turning Point, he was CMO of Peloton Therapeutics, which Merck acquired. Prior to joining Peloton, Dr. Hirmand served as CMO of Medivation through its acquisition by Pfizer. Before his 10-year tenure at Medivation, he held clinical development roles of increasing responsibility at Nuvelo, Inc., SuperGen, Inc., Tularik, Inc., and Theravance Biopharma, Inc.
“I’m excited to join Atavistik Bio’s board as the company prepares for its rapidly approaching clinical development milestones,” said Dr. Mohammad Hirmand. “As an industry, we’ve made important progress delivering breakthrough cancer treatments. However, there is enduring unmet need for significant patient populations, which underscores the opportunity to deliver more effective and safer treatment options. I believe Atavistik Bio’s focus on precision allostery, its pipeline of high value oncology targets, and its highly experienced team hold tremendous potential to fulfill many of these unmet needs.”
Dr. Hirmand received his M.D. from Harvard Medical School and his B.A. in Biological Sciences and Economics from Cornell University.
About Atavistik Bio
Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology. Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, Nextech Invest, and Lux Capital.
For more information : https://atavistikbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.